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Histamine H1 receptor (H1R) gene is upregulated in patients with pollinosis; its expression level is highly
correlated with the nasal symptom severity. Antihistamines are widely used as allergy treatments
because they inhibit histamine signaling by blocking H1R or suppressing H1R signaling as inverse ag-
onists. However, long-term treatment with antihistamines does not completely resolve toluene-2,4-
diisocyanate (TDI)-induced nasal symptoms, although it can decrease H1R gene expression to the
basal level, suggesting additional signaling is responsible for the pathogenesis of the allergic symptoms.
Here, we show that treatment with suplatast tosilate in combination with antihistamines markedly al-
leviates nasal symptoms in TDI-sensitized rats. Suplatast suppressed TDI-induced upregulation of IL-9
gene expression. Suplatast also suppressed ionomycin/phorbol-12-myristate-13-acetate-induced upre-
gulation of IL-2 gene expression in Jurkat cells, in which calcineurin (CN)/nuclear factor of activated T-
cells (NFAT) signaling is known to be involved. Immunoblot analysis demonstrated that suplatast
inhibited binding of NFAT to DNA. Furthermore, suplatast suppressed ionomycin-induced IL-9 mRNA
upregulation in RBL-2H3 cells, in which CN/NFAT signaling is also involved. These data suggest that
suplatast suppressed NFAT-mediated IL-9 gene expression in TDI-sensitized rats and this might be the
underlying mechanism of the therapeutic effects of combined therapy of suplatast with antihistamine.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pollinosis is a seasonal allergic rhinitis caused by hypersensi-
tivity to tree or grass pollens and affects >36 million people in the
United States and approximately 30% of the Japanese population (1,r Pharmacology, Institute of
e School, 1-78-1 Sho-machi,
4.
izuguchi).
rmacological Society.
e School, Khulna University,
. Production and hosting by Else2). It is characterized by paroxysmal repetitive sneezing, watery
rhinorrhea, and nasal blockage. Histamine is a major chemical
mediator of the allergic reaction, especially of the early-phase re-
action; its action is mainly mediated through the activation of
histamine H1 receptor (H1R).
Previously, we demonstrated that H1R gene expression is
strongly correlated with the allergic symptom severity in patients
with pollinosis (3) and that suppression of the upregulation of H1R
gene expression alleviated allergic symptoms in toluene-2,4-
diisocyanate (TDI)-sensitized rats (4e7). Furthermore, we showed
that histamine and phorbol-12-myristate-13-acetate (PMA) stim-
ulation increased H1R at both the mRNA and protein levels through
H1R activation in HeLa cells endogenously expressing H1R (8), andvier B.V. This is an open access article under the CC BY-NC-ND license (http://
H. Mizuguchi et al. / Journal of Pharmacological Sciences 130 (2016) 151e158152the protein kinase C-d (PKCd) signaling pathway was involved in
PMA-induced upregulation of HIR gene expression in HeLa cells (9).
Consequently, antihistamines are widely employed as the ﬁrst-line
treatment for nasal symptoms of allergic rhinitis because they
inhibit histamine signaling by blocking H1R or suppressing H1R
signaling as inverse agonists. However, we found that long-term
treatment with antihistamines alone could not completely
resolve TDI-induced nasal symptoms, although it decreased TDI-
induced upregulation of H1R gene expression to the basal level
(10), suggesting that other types of signaling are also responsible
for the pathogenesis of the allergic symptoms.
Suplatast tosilate (IPD-1151T) is an immunomodulator that
curbs eosinophil inﬁltration, IgE production, and allergic inﬂam-
mation by suppressing the IL-4 and IL-5 production (11, 12). Pre-
viously, we reported that treatment with suplatast alleviated TDI-
induced nasal symptoms and H1R and IL-4 mRNA elevation in
TDI-sensitized rats although suplatast did not curb histamine-
induced upregulation of H1R gene expression in HeLa cells (5).
Thus, it is probable that the anti-allergic activity of suplatast is not
through PKCd signaling suppression but through an unknown
signaling pathway suppression, and uncovering the unknown
signaling pathway could result in a new strategy for overcoming
the pathogenesis of this allergy.
In the present study, we investigated suplatast effects on allergic
symptoms in combination with antihistamines that suppress PKCd
signaling. We found that combined suplatast and antihistamine
treatment markedly suppressed nasal symptoms compared with
treatment with single drug. We also identiﬁed the previously un-
known signaling pathway suppressed by suplatast as being calci-
neurin (CN)/nuclear factor of activated T-cells (NFAT) signaling.
These data suggest the molecular mechanism of suplatast in the
combined therapy with antihistamine is the suppression of NFAT-
mediated IL-9 gene expression.
2. Materials and methods
2.1. Materials
Suplatast and its major metabolite M-1 were gifts from Taiho
Pharmaceutical and Sawai Pharmaceutical (Osaka). Monoclonal
anti-dinitrophenyl (DNP) IgE (clone SPE-7) and minimum essential
medium (MEM; with Earle's salts, L-glutamine, and nonessential
amino acids without NaHCO3) were from SigmaeAldrich (St. Louis,
MO, USA). RPMI-1640 mediumwas from Gibco BRL Life Technology
(Grand Island, NY, USA), and RNAiso Plus, PrimeScript RT Reagent
Kit, and Premix ExTaq were from Takara Bio Inc. (Kyoto). All other
chemicals were of analytical grade.
2.2. Toluene-2,4-diisocyanate-sensitized rats experiments
Six-week-old male Brown Norway rats (200e250 g; Japan SLC,
Hamamatsu) were used in this experiment. They were allowed free
access to water and food and were kept in a room at 25 C ± 2 C
and 55% ± 10% humidity with a 12-h lightedark cycle. They were
divided into three groups of four rats each: a control group, a group
sensitized with TDI (Wako Pure Chemical Industries Ltd., Tokyo),
and a test group. Sensitization with TDI was performed by the
method described by Shahriar et al. (Fig. 1) (5). In brief, 10 ml of a
10% solution of TDI in ethyl acetate was applied bilaterally on the
nasal vestibule of each rat once a day for ﬁve consecutive days. This
sensitization procedure was then repeated after 2 days. Nine days
after the second sensitization, TDI solutionwas again applied to the
nasal vestibule to provoke nasal symptoms. The control group was
sensitized and provoked with 10 ml of ethyl acetate using the same
procedure. Epinastine (24 mg/kg/day) and/or suplatast (80 mg/kg/day) were administered orally once a day for 2 weeks, starting 7
days after the ﬁrst sensitizationwith TDI (Fig.1). In accordancewith
the ﬁndings from our previous studies, we used these doses (80% of
the dose that we used in our previous studies) to produce a clear
combination effect of these two drugs. TDI-induced nasal symp-
toms were measured over the 10-min period immediately after TDI
provocation, including the number of sneezes and the nasal score,
which takes into account the extent of watery rhinorrhea, swelling,
and redness, measured on a scale ranging from zero to three
(Table 1). All experimental procedures were performed in accor-
dance with the guidelines of the Animal Research Committee of
Tokushima University.
2.3. Cell culture
Jurkat cells were cultured at 37 C under a humidiﬁed 5% CO2/
95% air atmosphere in RPMI-1640 supplemented with 10% fetal
bovine serum (FBS), 120 IU/mL penicillin (SigmaeAldrich) and
120 mg/mL streptomycin (SigmaeAldrich). RBL-2H3 cells were
cultured in MEM containing 10% FBS, 120 IU/mL penicillin, and
120 mg/mL streptomycin.
2.4. Real-time quantitative reverse transcription polymerase chain
reaction
Jurkat cells and RBL-2H3 cells cultured to 70% conﬂuency in six-
well dishes were treated with suplatast (36 h) or M-1 (24 h) before
ionomycin (1 mM) þ PMA (50 nM) (for Jurkat cells) or ionomycin
(1 mM for RBL-2H3 cells) stimulation. After a 6-h (for Jurkat cells) or
2-h (for RBL-2H3 cells) treatment, the cells were harvested and
total RNA was prepared using RNAiso Plus. For the IgE stimulation
experiments, RBL-2H3 cells were stimulated with 100 ng/mL of
anti-DNP IgE for 4 h. To determine the mRNA in the rats, the nasal
mucosa was collected in RNAlater 4 h after provocation with TDI
and stored at 80 C until used. The nasal mucosa was homoge-
nized using a Polytron (Model PT-K; Kinematica AG, Littau/Luzern,
Switzerland) in 10 volumes of RNAiso Plus. The RNA samples were
reverse transcribed to cDNA using a PrimeScript RT Reagent Kit.
TaqManprimers and the probewere designed using Primer Express
(Applied Biosystems, Foster City, CA, USA). Real-time PCR was
conducted using a GeneAmp 7300 Sequence Detection System
(Applied Biosystems). The sequences of the primers and TaqMan
probe are listed in Table 2. To standardize the starting material,
endogenous control human GAPDH and rodent GAPDH control
reagents (Applied Biosystems) were used, and data were expressed
as a ratio of GAPDH mRNA.
2.5. Preparation of nuclear DNA-bound proteins
Nuclear DNA binding proteins were isolated using the subcel-
lular protein fractionation kit (Thermo Fisher Scientiﬁc, Foster City,
CA, USA) according to the manufacture's instructions. Brieﬂy, Jurkat
cells cultured to 70% conﬂuency in 100 mm dishes were treated
with M-1 (24 h) or cyclosporin A (1 h) before ionomycin (1 mM)/
PMA (50 nM) stimulation. After a 30-min treatment with ion-
omycin/PMA, the cells were harvested and dissolved in cytoplasmic
extraction buffer provided by the kit, then, cytoplasmic, membrane,
nuclear soluble, nuclear DNA-bound, and cytoskeletal protein ex-
tracts were fractionated. The nuclear DNA-bound proteins were
separated by 12% SDS-PAGE. Immunoblot analysis was conducted
using NFATc1 antibody (sc-13033, Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Goat anti-rabbit IgG (HþL)-HRP conjugate (Bio-Rad,
Richmond, CA, USA) was used as the secondary antibody, and
proteins were visualized with an Immobilon Western Chemilumi-
nescent HRP substrate (Merck Millipore, Billerica, MA, USA).
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Fig. 1. Experimental protocol. The rats were sensitized by intranasal application of 10 ml of 10% toluene-2,4-diisocyanate (TDI) in ethyl acetate for 2 weeks. After 1 week, the nasal
symptoms were further provoked using 10 ml of 10% TDI. The control group was sensitized with ethyl acetate only. Epinastine (24 mg/kg/day) and/or suplatast (80 mg/kg/day) were
administered orally once a day for 2 weeks starting 7 days after the ﬁrst sensitization with TDI. The drugs were administered 1 h before the rats were treated with TDI.
Table 1
Criteria for grading the severity of toluene-2,4-diisocyanate-induced nasal responses in rats.
Nasal response Score
0 1 2 3
Watery rhinorrhea e At the nostril Between 1 and 3 Drops of discharge from the nose
Swelling and redness e Slightly swollen Between 1 and 3 Strong swelling and redness
Table 2
Nucleotide sequences for the primers and probes used in this study.
Primer/probe name Sequence
Rat IL-5 mRNA
Sense primer 50-CAGTGGTGAAAGAGACCTTGATACAG-30
Anti-sense primer 50-GAAGCCTCATCGTCTCATTGC-30
Probe FAM-TGTCACTCACCGAGCTCTGTTGACG-TAMRA
Rat IL-9 mRNA
Sense primer 50-GACGACCCATCATCAAAATGC-30
Anti-sense primer 50-CTGTGACATTCCCTCCTGGAA-30
Probe FAM-TTGTGCCTCCCCATCCCATCTGAT-TAMRA
Rat IL-13 mRNA and human IL-2 mRNA were determined using TaqMan gene
ampliﬁcation primers and probes (Rn00587615_m1 for IL-13 and Hs00174114_m1
for IL-2; Applied Biosystems).
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The results are shown as the mean ± S.E.M. Statistical analysis
was performed using unpaired t-tests or ANOVA with Dunnett's
test using GraphPad Prism software (GraphPad Software Inc., La
Jolla, CA, USA). P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Effect of epinastine and/or suplatast on TDI-induced nasal
symptoms in TDI-sensitized rats
Application of TDI for 3 weeks caused nasal symptoms in TDI-
sensitized rats (Fig. 2). As reported previously (10), pretreatment
with epinastine alone signiﬁcantly reduced TDI-induced sneezing
and the nasal score. Pretreatment with suplatast alone also signiﬁ-
cantly reduced nasal symptoms but was less effective than epinas-
tine. Combined treatment with epinastine and suplatast markedly
reduced TDI-induced sneezing and the nasal score (Fig. 2). The
control rats showed no nasal symptoms after TDI provocation.
3.2. Effect of suplatast on TDI-induced upregulation of Th2 cytokine
gene expression
Previously, we demonstrated that suplatast alleviated nasal
symptoms by inhibiting histamine signaling in TDI-sensitized ratsthrough the suppression of histamine- and IL-4-induced H1R gene
expression by the inhibitions of HDC and IL-4 gene transcriptions,
respectively (5). Thus, we investigated the effect of suplatast on
TDI-induced upregulation of other Th2 cytokine gene expressions
in TDI-sensitized rats. In addition to IL-4 gene, suplatast signiﬁ-
cantly suppressed TDI-induced upregulation of IL-5, IL-9, and IL-13
gene expressions (Fig. 3).
3.3. Effect of suplatast on ionomycin/PMA-induced upregulation of
IL-2 gene expression in Jurkat cells
As CN/NFAT signaling was involved in the regulation of Th2
cytokine gene expression (13e15), we investigated the effect of
suplatast on CN/NFAT signaling. Previous studies established that
CN/NFAT signaling is involved in IL-2 gene expression in T-cells, in
which NFAT activates IL-2 transcription in concert with AP-1 (14,
15). Therefore, to identify the signaling suppressed by suplatast,
we examined the effect of suplatast on ionomycin/PMA-induced
upregulation of IL-2 gene expression in Jurkat cells. Treatment
with ionomycin/PMA increased IL-2 mRNA expression in Jurkat
cells (Fig. 4). This ionomycin/PMA-induced IL-2 mRNA elevation
was signiﬁcantly suppressed by inhibitor of NFAT-CN association-6
(INCA-6) and cyclosporin A (Fig. 4), which are both known to inhibit
CN/NFAT signaling (13, 16, 17), conﬁrming the involvement of CN/
NFAT signaling. Pretreatment with suplatast or its major metabolite
M-1 (18) suppressed ionomycin/PMA-induced upregulation of IL-2
mRNA expression in a dose- and time-dependent manner (Fig. 4).
Our time-course studies also suggested the possibility that supla-
tast is a “prodrug” and that its metabolite M-1 may be the active
form (Fig. 4A and C).
3.4. Effect of suplatast on ionomycin-induced upregulation of IL-9
gene expression in RBL-2H3 cells
IgE alone activates several signaling pathways that lead to
cytokine production, including IL-4 and IL-13 (19). We found that
stimulation with IgE increased IL-9 gene expression in RBL-2H3
cells (Fig. 5A). As it was reported that stimulation with mono-
meric IgE increased intracellular Ca2þ concentration (20, 21), we
Fig. 2. Effect of epinastine and/or suplatast on toluene-2,4-diisocyanate (TDI)-induced nasal symptoms in TDI-sensitized rats. The rats were sensitized and provoked as described in
the Materials and Methods. The numbers of sneezes (A) and the nasal score (B) were measured over the 10-min period immediately after TDI provocation. The data are expressed as
means ± S.E.M. (n ¼ 4). **p < 0.01 vs. TDI; #p < 0.05, ##p < 0.01 vs. epinastine; $$p < 0.01 vs. suplatast.
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RBL-2H3 cells. A 2-h treatment with 1 mM ionomycin increased IL-
9 mRNA expression in RBL-2H3 cells. This IL-9 mRNA elevation
was signiﬁcantly suppressed by cyclosporin A and INCA-6 (Fig. 5B
and C), suggesting the involvement of CN/NFAT signaling. Pre-
treatment with suplatast or M-1 suppressed IL-9 mRNA elevation
in a dose- and time-dependent manner (Fig. 5DeG). These data
suggest that suplatast and M-1 suppress IL-9 gene upregulation by
inhibiting CN/NFAT signaling in IL-9 gene expression in RBL-2H3
cells.
3.5. Effect of suplatast on CN/NFAT signaling in Jurkat cells
In CN/NFAT signaling, NFAT is activated through its dephos-
phorylation by CN. Activated NFAT, then, translocated into the nu-
cleus, where they can cooperate with multiple transcriptional
partners such as AP-1 to regulate gene expression. We investigated
the effect of suplatast/M-1 on dephosphorylation of NFAT and
subsequent its nuclear translocation. Suplatast or M-1 did not
inhibit NFAT dephosphorylation by CN (data not shown). They did
not suppress ionomycin-induced NFAT translocation into the nu-
cleus in RBL-2H3 and Jurkat cells, either (data not shown). These
data suggest the possibility that suplatast/M-1 inhibit binding ofFig. 3. Effect of suplatast on toluene-2,4-diisocyanate (TDI)-induced upregulation of Th2 cyt
described in the Materials and Methods. The rats were sacriﬁced 4 h after provocation with T
determined by real-time quantitative RT-PCR. The data are expressed as means ± S.E.M. (nNFAT to the promoter DNA. As described above, our data suggest
that suplatast is a “prodrug” and M-1 may be the active form. So,
we, next, investigated the effect of suplatast/M-1 on the binding of
NFAT to DNA using M-1. We obtained the chromatin-bound nuclear
extract from PMA/ionomycin-stimulated Jurkat cells using the
subcellular protein fractionation kit. This fraction contains nuclear
proteins bound to chromatin in response to PMA/ionomycin stim-
ulation. Because M-1 did not inhibit activation or nuclear trans-
location of NFAT, NFAT should be recovered in this fraction and
immunoblot analysis of this fraction using anti-NFAT antibody can
assess if M-1 inhibits DNA binding of NFAT. Immunoblot analysis
after subcellular protein fractionation demonstrated that M-1
inhibited DNA binding of NFAT (Fig. 6).
4. Discussion
In the present study, we showed that treatment with suplatast
in combination with antihistamines markedly alleviates nasal
symptoms in TDI-sensitized rats. We demonstrated that the
expression level of the H1R gene is highly correlated with the
severity of the allergic symptoms in patients with pollinosis (3) and
that PKCd signaling is involved in histamine-induced upregulation
of H1R gene expression in HeLa cells (8, 9). However, suppression ofokine gene expression in TDI-sensitized rats. The rats were sensitized and provoked as
DI, and total RNA was isolated. The mRNA levels of IL-5 (A), IL-9 (B), and IL-13 (C) were
¼ 4). **p < 0.01 vs. TDI.
Fig. 4. Effect of suplatast (A and B) and its metabolite M-1 (C and D) on ionomycin/phorbol-12-myristate-13-acetate (PMA)-induced upregulation of IL-2 gene expression in Jurkat
cells. In A and C, Jurkat cells were treated with 500 mM of suplatast (A) or M-1 (B) at the given time intervals before ionomycin/PMA stimulation. In B and D, Jurkat cells were treated
with various concentrations of suplatast (B) or M-1 (D) 36 h (suplatast) or 24 h (M-1) before ionomycin/PMA stimulation. After 6 h of stimulation, the Jurkat cells were harvested,
and IL-2 mRNA was determined by real-time quantitative RT-PCR. As a positive control, Jurkat cells were treated with 50 mM of inhibitor of NFAT-CN association-6 (INCA-6) (A) or
0.5 mM of cyclosporin A (BeD) 1 h before ionomycin/PMA stimulation. CsA, cyclosporin A; P/I, PMA/ionomycin. The data are expressed as means ± S.E.M. (n ¼ 3e4). **p < 0.01 vs.
ionomycin/PMA.
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nasal symptoms in TDI-sensitized rats, suggesting the existence of
additional signaling responsible for the pathogenesis of the nasal
symptoms.
In addition to histamine, Th2 cytokines, including IL-4, IL-5, IL-9,
and IL-13, also play important roles in the pathogenesis of allergic
inﬂammation (22). Further, the existence and importance of
crosstalk of histamine with Th2 cytokines in allergic inﬂammation
have also been reported, in which histamine inﬂuences the
expression and action of Th2 cytokines; Th2 cytokines, in turn,
modulate the production and release of histamine (23, 24). We
demonstrated that prophylactic treatment with antihistamines
suppressed TDI-induced upregulation of both H1R and IL-4 mRNAs
in TDI-sensitized rats (10). We also showed that direct adminis-
tration of IL-4 into the nasal cavity of normal non-TDI-treated rats
upregulated the expression of H1R mRNA. Moreover, intranasal
histamine application caused an increase in IL-4 mRNA elevation in
the normal rats (5). In addition, we showed that the H1R expression
level was strongly correlated with that of IL-5 in patients with
pollinosis (25). These ﬁndings suggest that gene expressions of H1R
and Th2 cytokines are correlated and suppression of H1R gene
expression could affect the expression level of the Th2 cytokines. InTDI-sensitized rats, effects of suplatast and/or epinastine on the
nasal symptoms did not completely parallel with that on gene
expression. This could be the reason why we can see the strong
suppression of symptoms even if suppression of mRNA expression
in each protein is moderate.
Suplatast tosilate inhibits the production of Th2 cytokines such
as IL-4 and IL-5 (11, 12). Previously, we demonstrated that suplatast
suppressed TDI-induced upregulation of HDC gene expression in
TDI-sensitized rats, which decreased histamine synthesis and
resulted in the suppression of H1R mRNA elevation (5). Suplatast
also inhibited TDI-induced histamine release in the nasal lavage
ﬂuid. In addition, suplatast inhibited IL-4-induced upregulation of
H1R gene expression although it did not directly suppress PKCd
signaling (5). Here, we have shown that suplatast strongly sup-
pressed TDI- or ionomycin-induced upregulation of IL-9 gene
expression in TDI-sensitized rats (Fig. 3B) or in RBL-2H3 cells
(Fig. 5D and E), respectively. IL-9 is a pleiotropic cytokine produced
by activated helper T cells and activated mast cells (26e28), and it
promotes Th2-speciﬁc allergic responses, allergic inﬂammation,
and asthmatic symptoms (29, 30). Immunohistochemical analysis
showed stimulation with TDI induced inﬁltration of rat mast cell
protease-2 positive mast cells (data not shown), suggesting
Fig. 5. Effect of suplatast and its metabolite M-1 on monomeric IgE-stimulated (A) or ionomycin-induced (BeG) upregulation of IL-9 gene expression in RBL-2H3 cells. (A) RBL-2H3
cells were stimulated with 100 ng/mL of anti-DNP IgE. After 4 h of stimulation, the cells were harvested, and IL-9 mRNAwas determined by real-time quantitative RT-PCR. RBL-2H3
cells were treated with suplatast (500 mM) 72 h before IgE stimulation. In B and C, RBL-2H3 cells were treated with 0.5 mM of cyclosporin A (B) or 50 mM of inhibitor of NFAT-CN
association-6 (INCA-6) (C) 1 h before ionomycin stimulation. In D and F, RBL-2H3 cells were treated with 500 mM of suplatast (D) or 300 mM of M-1 (F) at the given time intervals
before ionomycin stimulation. In E and G, RBL-2H3 cells were treated with various concentrations of suplatast (E) or M-1 (G) 72 h (for suplatast) or 24 h (for M-1) before ionomycin
stimulation. After 2 h of stimulation, the RBL-2H3 cells were harvested, and IL-9 mRNA was determined by real-time quantitative RT-PCR. IO, ionomycin. The data are expressed as
the mean ± S.E.M. (n ¼ 3). *p < 0.05, **p < 0.01 vs. ionomycin.
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upregulates IL-4, IL-5, and IL-13 (31), suppression of IL-9 expres-
sion by suplatast may affect the expression levels of these Th2 cy-
tokines. These ﬁndings suggest that the suppressive effect of
suplatast on the nasal symptoms is partially due to the indirect
suppression of PKCd signaling, however, most of the effect isderived from the suppression of the signaling responsible for Th2
cytokine gene expression (Fig. 4).
CN/NFAT signaling plays a central role in inducible gene
transcription during immune response (32, 33). NFAT was ﬁrst
identiﬁed as a factor that binds to the distal antigen-receptor
response element of the human IL-2 promoter (34e36). In
Fig. 6. Effect of M-1 on PMA/ionomycin-induced DNA binding of activated NFAT. Jurkat
cells were treated with M-1 (24 h) or cyclosporin A (1 h) before ionomycin (1 mM)/PMA
(50 nM) stimulation. After a 30-min treatment, the cells were harvested and nuclear
DNA-bound protein extracts were prepared using the subcellular protein fractionation
kit. The proteins were separated by 12% SDS-PAGE and immunoblot analysis was
performed using NFATc1 antibody. P þ I, PMA þ ionomycin.
H. Mizuguchi et al. / Journal of Pharmacological Sciences 130 (2016) 151e158 157addition, it has also been reported that NFAT binds to the pro-
moter region of many cytokines, including IL-4, IL-5, and IL-13
(13e15). As suplatast suppressed TDI-induced upregulation of
Th2 cytokine gene expression in our previous study, we speculate
that the suppressive effect of suplatast is through the suppression
of CN/NFAT signaling. Suplatast suppressed ionomycin/PMA-
induced upregulation of IL-2 gene expression in Jurkat cells.
NFAT and AP-1 have been reported to cooperatively regulate
transcription of the IL-2 gene (14, 15). As suplatast does not
suppress histamine-induced upregulation of H1R gene expression
in HeLa cells, in which the activation of AP-1 is indispensable for
gene transcription (5, 9), it is unlikely that suplatast suppresses
the activation of c-Fos, one of the subunits of AP-1, in Jurkat cells.
To understand the mechanism of action of suplatast, we investi-
gated the effect of suplatast on CN/NFAT signaling in Jurkat cells.
Suplatast/M-1 did not inhibit dephosphorylation of NFAT by CN
and subsequent its nuclear translocation (data not shown).
However, immunoblot analysis using M-1 after subcellular pro-
tein fractionation demonstrated that M-1 inhibited binding of
NFAT to DNA (Fig. 6). This data strongly suggest that suplatast/M-
1 suppress CN/NFAT signaling although it is not clear, so far, if
suplatast inhibits binding of NFAT to DNA directly or through
modiﬁcation of chromatin architecture. It was reported that
combination with suplatast could reduce the dose or even negate
the need for using tacrolimus ointment, which inhibits CN/NFAT
signaling (37). Data that suplatast inhibits CN/NFAT signaling may
explain why suplatast can use as a substitute for tacrolimus in
treating atopic dermatitis.
Although involvement of CN/NFAT signaling in IL-9 gene
expression has not been fully elucidated, our data suggest that the
CN/NFAT signaling pathway is possibly involved in ionomycin-
induced upregulation of IL-9 gene expression in RBL-2H3 cells.
Recently, it was reported that NFAT and NF-kB synergistically
enhance IL-9 transcription in CD4þ cells, during which NFATcreates
an accessible chromatin platform for the recruitment of NF-kB onto
the IL-9 promoter (38). Although we cannot exclude the additional
involvement of NF-kB in the ionomycin-induced IL-9 upregulation
in RBL-2H3 cells, the suppressive effect of suplatast may be exerted
through the inhibition of CN/NFAT signaling.
These data suggest that suplatast suppressed NFAT-mediated IL-
9 gene expression in TDI-sensitized rats and this might be the
underlying mechanism of the therapeutic effects of combined
therapy of suplatast with antihistamine.Conﬂicts of interest
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